Approved comparison material connected to this topic.
3 total recordsSource comparisons are presented without a generated winner.
JCEM 2023 (n=142, ages 65–78) 500mcg nightly 24 weeks +2.8kg (DEXA) +68% from baseline 8% mild injection site reaction Largest sarcopenia-specific trial; statistically significant lean mass gain with minimal A…
The sermorelin sarcopenia research mechanism differs fundamentally from exogenous growth hormone administration. And the distinction matters clinically. Exogenous GH (recombinant human growth hormone) bypasses…
Aged rodents (24-month) 300 Daily (evening) 12 weeks Grip strength, lean mass +8.4% vs control +22% muscle IGF-1 Best-validated preclinical model. Dose aligns with circadian GH peak and produces significant fu…